SEC
SlamSEC
SearchBrowseEarnings

Immunome Inc.

Nasdaq:IMNM
Pharmaceutical Preparations·BOTHELL, WA
OverviewAll FilingsSum FinCreditInsidersGovernance
OverviewAll FilingsSum FinCreditInsidersGovernance

Summary Financials

The immunome is the set of genes that code for proteins which constitute the immune system, excluding those that are widespread in other cell types, and not involved in the immune response itself. It is further defined as the set of peptides derived from the proteome that interact with the immune system.

Revenue
$9.0M
-35.5% YoY
FY 2025
Adj. EBITDA
-$304.2M
-3365.0% margin
FY 2025
Net Income
-$293.0M
-3240.4% margin
FY 2025
EPS (Diluted)
-$5.00
FY 2025
Stock Price
$21.32
+1.3%
2026-03-09
52W Range
$5.15 – $27.65
P/E Ratio
-4.3x
Market Cap
$2.4B
Cash
$143.4M
FY 2025
Total Debt
$134,000
FY 2021
Net Cash
$143.2M
FY 2021
Enterprise Value
$2.3B
Debt / EBITDA
0.5x
FY 2025
EV / EBITDA
-7.5x
Employees
—